title: Pulmonary effects of chronic exposure to liposome aerosols in mice.
abstract: Administering liposome-encapsulated drugs by aerosols could be a feasible way of targeting drugs to the lung, specifically to pulmonary alveolar macrophages (AM). In the mouse model, we characterized uptake of carboxyfluorescein- (CF-) labeled liposomes by AM in vivo after acute inhalation of liposome aerosols, and the effects of chronic exposure to liposome aerosols on lung histology and AM function. Mice were placed in a nose-only exposure module and exposed to liposome or saline aerosols for 1 h per day, 5 days per week, for 4 weeks. Five mice of both the experimental and control groups were removed weekly and their lungs examined. Liposomes were made from hydrogenated soy phosphatidylcholine (HSPC) at 50 mg/mL. In vivo uptake of liposomes by AM was documented by fluorescence microscopy and flow cytometry of bronchoalveolar lavage (BAL). A consistent amount of 1-3 micrograms of lipid inhaled per dosing per mouse was estimated from fluorescence measurements. Addition of Triton X-100 to BAL caused a significant increase in fluorescence intensity, indicating that liposomes remained intact in the lung for a period of time. The chronic inhalation study showed no histologic changes of the lung or untoward effects on the general health or survival of animals. AM phagocytic function, intracellular killing, and fatty acid composition were not affected. Transmission electron microscopy and morphometry (computerized image analysis) of AM likewise showed no alterations as a result of the treatment. It was concluded that AM uptake of liposomes delivered by aerosol was operant in vivo. This finding validates the concept of alveolar macrophage-directed delivery of liposome-encapsulated agents to the lung via inhalation. It was also concluded that chronic liposome aerosol inhalation in mice produced no untoward effects on survival, histopathology, and macrophage function. These data confirm and extend prior findings regarding the functional and morphologic interactions of liposomes with AM in vitro (Gonzalez-Rothi et al., Exp. Lung Res. 17:687-705, 1991).
authors.affiliation: Pulmonary Division, College of Medicine, University of Florida, Gainesville 32610.
authors.forename: M A
authors.initials: MA
authors.lastname: Myers
authors.forename: D A
authors.initials: DA
authors.lastname: Thomas
authors.forename: L
authors.initials: L
authors.lastname: Straub
authors.forename: D W
authors.initials: DW
authors.lastname: Soucy
authors.forename: R W
authors.initials: RW
authors.lastname: Niven
authors.forename: M
authors.initials: M
authors.lastname: Kaltenbach
authors.forename: C I
authors.initials: CI
authors.lastname: Hood
authors.forename: H
authors.initials: H
authors.lastname: Schreier
authors.forename: R J
authors.initials: RJ
authors.lastname: Gonzalez-Rothi
mesh_terms: D000281:Administration, Intranasal; D000336:Aerosols / Q000008:administration & dosage*; D000818:Animals; D004337:Drug Carriers; D005227:Fatty Acids / Q000032:analysis; D008081:Liposomes; D008168:Lung / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D016676:Macrophages, Alveolar / Q000378:metabolism* / Q000648:ultrastructure; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects; D010713:Phosphatidylcholines; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000336:Aerosols; D004337:Drug Carriers; D005227:Fatty Acids; D008081:Liposomes; D010713:Phosphatidylcholines